Transfusion medicine handbook

[1]

CSL Behring (NZ) Limited, "New Zealand Data Sheet: Beriplex NZ 500 IU," 21 11 2024. [Online]. Available: https://www.medsafe.govt.nz/profs/Datasheet/b/BeriplexNZinj.pdf. [Accessed 09 01 2025].

[2]

CSL Behring (Australia) Pty Ltd, "NEW ZEALAND DATA SHEET - Alburex 5 NZ," 14 December 2023. [Online]. Available: https://www.medsafe.govt.nz/profs/Datasheet/a/Alburex5inf.pdf. [Accessed 01 February 2024].

[3]

CSL Behring (Australia) Pty Ltd, "NEW ZEALAND DATA SHEET - Alburex 20 NZ," 01 June 2023. [Online]. Available: https://www.medsafe.govt.nz/profs/datasheet/a/alburex20NZinf.pdf. [Accessed 01 February 2024].

[4]

[5]

Ministry of Health (New Zealand), "Immunisation Handbook 2025 (version 2)," 14 04 2025. [Online]. Available: https://www.tewhatuora.govt.nz/for-health-professionals/clinical-guidance/immunisation-handbook. [Accessed 22 04 2025].

[6]

Health NZ Te Whatu Ora, "Immunisation Handbook/ 8. Hepatitis A," 17 12 2024. [Online]. Available: https://www.tewhatuora.govt.nz/for-health-professionals/clinical-guidance/immunisation-handbook/8-hepatitis-a. [Accessed 22 04 2025].

[7]

Health NZ Te Whatu Ora, "Communicable Disease Control Manual / Rubella," 08 01 2024. [Online]. Available: https://www.tewhatuora.govt.nz/for-health-professionals/clinical-guidance/communicable-disease-control-manual/rubella#management-of-case. [Accessed 22 04 2025].

[8]

Health NZ Te Whatu Ora, "Immunisation Handbook/ 12. Measles," 14 04 2025. [Online]. Available: https://www.tewhatuora.govt.nz/for-health-professionals/clinical-guidance/immunisation-handbook/12-measles#12-8-public-health-measures. [Accessed 22 04 2025].

[9]

CSL Behring (Australia) Pty Ltd, "New Zealand Data Sheet- Hepatitis B Immunoglobulin-VF," 03 Jun 2021. [Online]. Available: https://www.nzblood.co.nz/assets/Transfusion-Medicine/PDFs/160S011.pdf. [Accessed 16 03 2023].

[10]

CSL Behring (Australia) Pty Ltd, "New Zealand Data Sheet- Zoster Immunoglobulin-VF," 13 Apr 2021. [Online]. Available: https://www.nzblood.co.nz/assets/Transfusion-Medicine/PDFs/160S010.pdf. [Accessed 16 03 2023].

[11]

CSL Behring (Australia) Pty Ltd, "New Zealand Data Sheet- Tetanus Immunoglobulin-VF," 09 Apr 2021. [Online]. Available: https://www.nzblood.co.nz/assets/Transfusion-Medicine/PDFs/160S015.pdf. [Accessed 16 03 2023].

[12]

Centers for Disease Control and Prevention, "Tetanus," 29 Aug 2022. [Online]. Available: https://www.cdc.gov/tetanus/clinicians.html. [Accessed 16 03 2023].

[13]

CSL Behring, "Tetagam® P package insert CSL Behring. G1381 G26," November 2014. [Online]. Available: https://www.hpra.ie/img/uploaded/swedocuments/5841f694-a3a6-4077-8709-63decf20bdaf.pdf.

[14]

CSL Behring (Australia) Pty Ltd, "New Zealand Data Sheet- Zoster Immunoglobulin-VF," 13 Apr 2021. [Online]. Available: https://www.nzblood.co.nz/assets/Transfusion-Medicine/PDFs/160S010.pdf. [Accessed 16 03 2023].

[15]

Starship Child Health, "Varicella zoster (chicken pox) post exposure prophylaxis," 08 Dec 2022. [Online]. Available: https://starship.org.nz/guidelines/zoster-immunoglobulin/. [Accessed 16 03 2023].

[16]

National Child Cancer Network, "IMMUNISATION OF CHILDREN DURING and AFTER CANCER THERAPY," 16 Jul 2021. [Online]. Available: https://media.starship.org.nz/catch-up-immunisations-for-children-with-cancer/Immunisation_of_children_during_and_after_cancer_090522.pdf. [Accessed 16 03 2023].

[17]

CSL Behring (NZ) Ltd, "New Zealand Data Sheet- Rh(D) Immunoglobulin-VF," 08 Jun 2022. [Online]. Available: https://www.nzblood.co.nz/assets/Transfusion-Medicine/PDFs/160S009.pdf. [Accessed 16 03 2023].

[18]

H. Pilgrim, M. Lloyd-Jones and A. Rees, "Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.," Health Technology Assessment, vol. 13, no. 10, pp. 1-103, 2009.

[19]

RANZCOG, "Guidelines for the use of Rh(D) Immunoglobulin (Anti-D) in obstetrics," Jul 2019. [Online]. Available: https://ranzcog.edu.au/wp-content/uploads/2022/05/Anti-D-guidelines_July-2021.pdf. [Accessed 16 03 2023].

[20]

CSL Behring GmbH, "Summary of Product Characteristics- Rhophylac," 18 Jul 2019. [Online]. Available: https://mhraproducts4853.blob.core.windows.net/docs/4dd264b4d020ff628ab2d97ca7a8e40940036ce7. [Accessed 17 03 2023].

[21]

CSL Behring (NZ) Limited, "New Zealand Data Sheet- Privigen NZ," 31 10 2024. [Online]. Available: https://www.medsafe.govt.nz/profs/datasheet/p/privigeninj.pdf. [Accessed 22 04 2025].

[22]

CSL Behring (NZ) Limited, "New Zealand Data Sheet- Privigen," 31 10 2024. [Online]. Available: https://www.medsafe.govt.nz/profs/datasheet/p/privigeninj.pdf. [Accessed 22 04 2025].

[23]

Pharmaco (N.Z.) Ltd, "GAMUNEX- New Zealand Data Sheet," 02 Aug 2018. [Online]. Available: https://medsafe.govt.nz/Profs/datasheet/g/gamunexinf.pdf. [Accessed 31 03 2023].

[24]

CSL Behring (NZ) Ltd, "Intragam P 6% solution for infusion," 23 Mar 2018. [Online]. Available: https://www.nzblood.co.nz/assets/Transfusion-Medicine/PDFs/160S001.pdf. [Accessed 17 03 2023].

[25]

Public Health England, "Guidelines on Post-Exposure Prophylaxis for measles," 01 Jun 2019. [Online]. Available: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/814203/Guidance_for_measles_post-exposure_prophylaxsis.pdf. [Accessed 17 03 2023].

[26]

Health NZ Te Whatu Ora, "Immunisation Handbook / 9. Hepatitis B / 9.8. Public health measures," 14 04 2025. [Online]. Available: https://www.tewhatuora.govt.nz/for-health-professionals/clinical-guidance/immunisation-handbook/9-hepatitis-b#9-8-public-health-measures. [Accessed 22 04 2025].